Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3432 | SARS-CoV-2 non-immune Plasma Wiki | 1.00 |
| drug302 | Anti- SARS-CoV-2 Plasma Wiki | 1.00 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003289 | Convalescence NIH | 0.38 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a multicenter, randomized, double-blind, placebo-controlled phase 2 study of IC14, an antibody to CD14, in reducing the severity of respiratory disease in hospitalized COVID-19 patients.
Description: Days alive and free of any episodes of acute respiratory failure through Day 22 defined by need for high-flow nasal cannula, noninvasive positive-pressure ventilation, endotracheal intubation and mechanical ventilation, and extracorporeal membrane oxygenation
Measure: Acute respiratory failure Time: Day 1-22Description: Defined as time to the first day that a subject is in categories 6, 7, or 8 on the Eight-Point Ordinal Scale. The Eight-Point Ordinal Scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high-flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen-requiring ongoing medical care (COVID-19-related or otherwise); 6) Hospitalized, not requiring supplemental oxygen-no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities.
Measure: Time to clinical improvement Time: Day 1-29Description: Proportion of patients alive and free of any episode of acute respiratory failure through Days 8, 15, 22, and 29
Measure: Acute respiratory failure Time: Days 1-8, 1-15, 1-22, 1-29Description: Proportion of patients alive and free of invasive mechanical ventilation through Days 8, 15, 22, and 29
Measure: Invasive mechanical ventilation Time: Days 1-8, 1-15, 1-22, 1-29Description: Days alive and free of acute respiratory failure through Days 15 and 29
Measure: Acute respiratory failure Time: Days 1-15 and 1-29Description: Days alive and free of invasive mechanical ventilation through Days 15, 22, and 29
Measure: Invasive mechanical ventilation Time: Days 1-15, 1-22, 1-29Description: Days alive and hospitalized through Day 29
Measure: Hospitalization Time: Days 1-29Description: Change in Sequential Organ Failure Assessment (SOFA) score (range 0 [best] to 24 [worst]) from baseline to Day 8, Day 15, and Day 22
Measure: Sequential Organ Failure Assessment Time: Days 1-8, 1-15, 1-22Description: Worst SOFA score from baseline to Day 22
Measure: Sequential Organ Failure Assessment Time: Days 1-22Description: Proportion of patients alive and discharged from the hospital at Days 15 and 29.
Measure: Hospitalization Time: Days 1-15, 1-29Description: Mean change in the eight-point ordinal scale (1 [worst] to 8 [best]) through Day 29
Measure: Ordinal Scale Time: Days 1-29Description: Time to improvement in one category from baseline using an eight-point ordinal scale (1 [worst] to 8 [best]) through Day 29.
Measure: Time to clinical improvement Time: Days 1-29Description: Time to improvement in two categories from baseline using an eight-point ordinal scale (1 [worst] to 8 [best]) through Day 29.
Measure: Time to clinical improvment Time: Days 1-29Description: Time to recovery through Day 29. Day of recovery is defined as the first day on which the subject satisfies one of categories 6-8 from the ordinal scale.
Measure: Time to recovery Time: Days 1-29Description: Change in C-reactive protein in blood on Days 4 and 8 compared to baseline (from normal < 10 mg/L [normal] to >10 mg/L [worse])
Measure: Change in C-reactive protein Time: Day 4 compared to baseline; Day 8 compared to baselineDescription: Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events
Measure: Adverse events Time: Days 1-60Description: Cumulative incidence of serious adverse events
Measure: Serious adverse events Time: Days 1-60Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports